The molecular and cellular basis of radiosensitivity: Implications for understanding how normal tissues and tumors respond to therapeutic radiation

Cancer Investigation

Volumn 17, Issue 1, 1999, Pages 56-72

  Rosen, Eliot M ^a   Fan, Saijun ^a   Rockwell, Sara ^b   Goldberg, Itzhak D ^a  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Ataxia telangiectasia; Cancer; Cytokines; DNA damage; Growth factors; Late effects; P53; Radiation therapy (radiotherapy)

Indexed keywords

APOPTOSIS; CANCER; CANCER RADIOTHERAPY; DNA DAMAGE; HUMAN; PRIORITY JOURNAL; RADIATION CARCINOGENESIS; RADIOSENSITIVITY; REVIEW; TUMOR RECURRENCE;

EID: 0032966188     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1080/07357909909011718     Document Type: Review

References (138)

1. Suit H: Assessment of the impact of local control on clinical outcome. Front Radiat Ther Oncol 29:17-23, 1996.
2. Hellman S: Principles of cancer management: Radiation therapy. In: Cancer. Principles and Practice of Oncology, 5th ed., edited by VT DeVita, S Hellman, SA Rosenberg, Philadelphia, Lippincott-Raven Publishers, 1997, pp 307-332.
3. Lindegaard JC, Overgaard J, Bentzen SM, et al: Is there a radiobiologic basis for improving the treatment of advanced stage cer-vical cancer? J Natl Cancer Inst Monogr 21:105-112, 1996.
4. Thames HD, Peters LJ, Ang KK: Time-dose considerations for normal tissue tolerance. Front Radiat Ther Oncol 23:113-130, 1989.
5. Withers HR, Peters LJ, Kogelnik HD: The pathobiology of late effects of irradiation. In: Radiation Biology in Cancer Research, edited by RE Meyn, HR Withers, New York, Raven Press, 1980, pp 439-448.
6. Withers HR, Mason KA, Thames HD: Late radiation response by kidney assayed by tubule-cell survival. Brit J Radiol 59:587-595, 1986.
7. Fowler JF: Dose response curves for organ function or cell survival. Radiol 56:497-500, 1983.
8. Wheldon TE, Michalowski AS, Kirk J: The effect of irradiation on function in self-renewing normal tissues with differing proliferative organization. Brit J Radiol 55:759-766, 1982.
9. Hopewell JW: The importance of vascular damage in the development of late radiation effects in normal tissues. In: Radiation Biology in Cancer Research, edited by RE Meyn, HR Withers, New York, Raven Press, 1980, pp 449-459.
10. Casarett GW: Radiation Histopathology, Vol. I. Boca Raton, CRC Press, 1980, pp 39-50.
11. Morris GM: Review article: effects of radiation on the cell proliferation kinetics of epithelial tissues - therapeutic implications. Br J Radiol 69:795-803, 1996.
12. Bloomer WD, Hellman S, Medical intelligence. Current concepts. Normal tissue responses to radiation therapy. N Engl J Med 293:80-83, 1975.
13. Rockwell S, Roberts KB: Radiation pneumonitis. In: Pulmonary Diseases and Disorders, 3rd ed., edited by AP Fishman, New York, McGraw-Hill Book Co., in press.
14. Fletcher GH. Textbook of Radiotherapy, 3rd ed., Philadelphia, Lea and Feibiger, 1980, pp 181-184.
15. Hall EJ: Effects of radiation on the embryo and fetus. In: Radiobiology for the Radiologist, 3rd ed., Philadelphia, J.B. Lippincott Co., 1988, pp 445-465.
16. Hellman S, Botnick LE. Stem cell depletion: an explanation of the late effects of cytotoxins. Int J Radiat Oncol Biol Phys 2: 181-184, 1977.
17. van der Kogel AJ: Mechanisms of late radiation injury in the spinal cord. In: Radiation Biology in Cancer Research, edited by RE Meyn, HR Withers, New York, Raven Press, 1980, pp 461-470.
18. Land CE: Studies of cancer and radiation dose among atomic bomb survivors. The example of breast cancer. JAMA 274:402-407, 1995.
19. Pierce DA, Shimizu Y, Preston DL, et al: Studies of the mortality of atomic bomb survivors. Report 12, Part I. Cancer: 1950-1990. Radiat Res 146:1-27, 1996.
20. Chackraborty R, Sankaranarayanan K: Cancer predisposition, radiosensitivity, and the risk of radiation-induced cancers. II. A Mendelian single-locus model of cancer predisposition and radiosensitivity for predicting cancer risks in populations. Radiat Res 143:293-301, 1995.
21. Stoppa-Lyonnet D, Aurias A: Ataxia telangiectasia: what impact in clinical oncology? Bull Cancer Paris 79:645-650, 1992.
22. Jones LA, Scott D, Cowan R, et al: Abnormal radiosensitivity of lymphocytes from breast cancer patients with excessive normal tissue damage after radiotherapy: chromosome aberrations after low dose-rate irradiation. Int J Radiat Biol 67:519-528, 1995.
23. Roa B, Boyd AA, Volcik K, et al: Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14:188-190, 1996.
24. Hellman S, Weichselbaum RR: Radiation oncology. JAMA 271: 1712-1714, 1994.
25. Vijayakumar S, Chen CT: Implementation of three dimensional conformal radiation therapy: prospects, opportunities, and challenges. Int J Radiat Oncol Biol Phys 33:979-983, 1995.
26. Stuschke M, Thames HD: Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. Int J Radiat Oncol Biol Phys 37:259-267, 1997.
27. Suit H, Urie M: Proton beams in radiation therapy. J Natl Cancer Inst 84:155-164, 1992.
28. Levine AJ: P53, the cellular gatekeeper for growth. Cell 88:293-299, 1997.
29. Paulovich AG, Toczynski DP, Hartwell GH: When checkpoints fail. Cell 88:315-321, 1997.
30. Kastan MB: Molecular biology of the cell: The cell cycle. In: Cancer. Principles and Practice of Oncology, 5th ed., edited by VT DeVita, S Hellman, SA Rosenberg, Philadelphia, Lippincott-Raven Publishers, 1997, pp 121-134.
31. Hunter T: Oncoprotein networks. Cell 88:333-346, 1997.
32. Perkins AS, Stern DF: Molecular biology of cancer: Oncogenes. In: Cancer. Principles and Practice of Oncology, 5th ed., edited by VT DeVita, S Hellman, SA Rosenberg, Philadelphia, Lippincott-Raven Publishers, 1997, pp 79-102.
33. Helmbrook DC, Oliff A, Gibbs JB: Essentials of signal transduction. In: Cancer. Principles and Practice of Oncology, 5th ed., edited by VT DeVita, S Hellman, SA Rosenberg, Philadelphia, Lippincott-Raven Publishers, 1997, pp 35-46.
34. Wertz IE, Hanley MR: Diverse molecular provocation of cell death. Trends Biochem Sci 21:359-364, 1996.
35. Vaux DL: CED-4 - The third horseman of apoptosis. Cell 90: 389-390, 1997.
36. Nagata S: Apoptosis by death factor. Cell 88:355-366, 1997.
37. Meyn RE, Stephens LC, Milas L. Programmed cell death and radioresistance. Cancer Metastasis Rev 15:119-131, 1996.
38. Reed JC: Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 7:541-546, 1995.
39. Bergman PJ, Harris D: Radioresistance, chemoresistance, and apoptosis resistance. The past, present, and future. Vet Clin North Am Small Anim Pract 27:47-57, 1997.
40. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299, 1995.
41. Buckbinder L, Talbott R, Valesco-Miguet S, et al: Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377: 646-649, 1995.
42. El-Deiry WS, Tokino T, Velculescu VE, et al: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993.
43. Smith ML, Chen IT, Zhan Q, et al: Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266:1376-1379, 1994.
44. Kastan MB, Zhan Q, El-Deiry WS, et al: A mammalian cell cycle checkpoint pathway utilizing p53 and Gadd45 is defective in ataxia-telangiectasia. Cell 71:587-597, 1992.
45. Maity A, McKenna WG, Muschel RJ: The molecular basis for cell cycle delays following ionizing radiation: a review. Radiother Oncol 31:1-13, 1994.
46. O'Connor PM, Jackman J, Jondle D, et al: Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkin's lymphoma cell lines. Cancer Res 53:4776-4780, 1993.
47. 2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 88:956-965, 1996.
48. Fan S, Smith ML. Rivet DJ II, et al: Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55:1649-1654, 1995.
49. Nishii K, Kabarowski JH, Gibbons DL, et al: ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. Oncogene 13:2225-2234, 1996.
50. Yuan ZM, Huang Y, Whang Y, et al: Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. Nature 382: 272-274, 1996.
51. Weinert TA, Hartwell LH: The RAD9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae. Science 241:317-322, 1988.
52. Haupt Y, Rowan S, Shaulian E, et al: Induction of apoptosis in HeLa cells by transactivation deficient p53. Genes Dev 9:2170-2183, 1995.
53. Sakakura C, Sweeney EA, Shirahama, et al: Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. Int J Cancer 67:101-105, 1996.
54. Runnebaum IB, Nagarajan M, Bowman M, et al: Mutations in p53 as potential molecular markers for breast cancer. Proc Natl Acad Sci USA 88:10657-10661, 1991.
55. Ludwig RL, Bates S, Voudsen KH: Differential activities of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol 16:4952-4960, 1996.
56. Bargou RC, Daniel PT, Mapara MY, et al: Expression of the bcl-2 gene family in normal and malignant breast tissue: bax-alpha expression in tumor cells correlates with resistance toward apoptosis. Int J Cancer 60:854-859, 1995.
57. Rampino N, Yamamoto H, Ionov Y, et al: Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275:967-969, 1997.
58. Wang XW, Yeh H, Schaeffer L, et al: p53 modulation of TFIIH associated nucleotide excision repair activity. Nat Genet 10: 188-195, 1995.
59. Scott D, Spreadborough AR, Jones LA, et al: Chromosomal radiosensitivity in G2-phase lymphocytes as an indicator of cancer predisposition. Radiat Res 145:3-16, 1996.
60. Sakata Y, Aoki Y, Kumakura Y, et al: Radiation therapy for patients with xeroderma pigmentosum. Radiat Med 14:87-90, 1996.
61. Murray D, Rosenberg E: The importance of ERCC1/ERCC4 [XPF] complex for hypoxic-cell radioresistance does not appear to derive from its participation in the nucleotide excision repair pathway. Mutat Res 364:217-226, 1996.
62. Thompson LH, Brookman KW, Jones NJ, et al: Molecular cloning of the human XRCC-1 gene, which corrects DNA strand break repair and sister chromatid exchange. Mol Cell Biol 10: 6160-6171, 1990.
63. Caldecott KW, Aoufouchi S, Johnson P, et al: XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly (ADP-ribose) polymerase, and DNA ligase III is a novel molecular 'nick-sensor' in vitro. Nucleic Acids Res 24:4387-4394, 1996.
64. Dunphy EJ, Beckett MA, Thompson LH, et al: Expression of the polymorphic human DNA repair gene XRCC1 does not correlate with radiosensitivity in the cells of human head and neck tumor cell lines. Radiat Res 130:166-170, 1992.
65. Savitsky K, Bar-Shira A, Gilad S, et al: A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268: 1749-1753, 1995.
66. Savitsky K, Sfez S, Tagle DA, et al: The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum Mol Genet 4:2025-2032, 1995.
67. Xu Y, Baltimore D: Dual roles of ATM in the cellular response to radiation and in cell growth control. Genes Dev 10:2401-2410, 1996.
68. Morgan SE, Lovly C, Pandita TK, et al: Fragments of ATM which have dominant-negative or complementing activity. Mol Celt Biol 17:2020-2029, 1997.
69. Gilad S, Khosravi R, Shkedy D, et al: Predominance of null mutations in ataxia telangiectasia. Hum Mol Genet 5:433-439, 1996.
70. Ross GM, Eady JJ, Mithal NP, et al: DNA strand break rejoining defect in xrs-6 is complemented by transfection with the human Ku80 gene. Cancer Res 55:1235-1238, 1995.
71. Kirchgessner CU, Patil CK, Evans JW, et al: DNA-dependent kinase (p350) as a candidate gene for the murine SCID defect. Science 267:1178-1183, 1995.
72. Miki Y, Swensen J, Shattuck-Eidens D, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71, 1994.
73. Tavtigian SV, Simard J, Rommens J, et al: The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 12:333-337, 1996.
74. Scully R, Chen J, Plug A, et al: Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88:265-275, 1997.
75. Sharan SK, Morimatsu M, Albrecht U, et al: Embryo lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386:804-810, 1997.
76. Rajan JV, Wang M, Marquis ST, et al: Brca2 is coordinately regulated with Brcal during proliferation and differentiation in mammalian epithelial cells. Proc Natl Acad Sci USA 93:3078-3083, 1996.
77. Shao N, Chai YL, Shyam E, et al: Induction of apoptosis by tumor suppressor protein BRCA1. Oncogene 13:1-7, 1996.
78. Koonin VF, Altschul SF, Bork P: BRCA1 protein products: functional motifs. Nat Genet 13:266-267, 1996.
79. Scully R, Chen J, Ochs RL, et al: Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 90:425-435, 1997.
80. Tirkkonen M, Johannson O, Agnarsson BA, et al: Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 57:1222-1227, 1997.
81. Hakem R, de la Pompa JL, Sirard C, et al: The tumor suppressor gene Brcal is required for embryonic cellular proliferation in the mouse. Cell 85:1009-1023, 1996.
82. Karp SE, Tonin PN, Begin LR, et al: Influence of BRCA1 mutations on nuclear grade and estrogen status of breast carcinoma in Ashkenazi Jewish women. Cancer 80:435-441, 1997.
83. Weichselbaum RR, Beckett MA, Vokes EE, et al: Cellular and molecular mechanisms of radioresistance. Cancer Treat Res 74: 131-140, 1995.
84. Sklar MD: The ras-oncogenes increase the intrinsic radioresistance of NIH-3T3 cells to ionizing radiation. Science 239:645-657, 1988.
85. McKenna WG, Weiss MC, Endlich B, et al: Synergistic effect of the v-myc oncogene with H-ras on radioresistance. Cancer Res 50:97-102, 1990.
86. Kaufftnanzeh A, Rodriguezviciana P, Ulrich E, et al: Suppression of c-Myc induced apoptosis by Ras signalling through P13K and PKB. Nature 385:544-548, 1997.
87. Bristow RG, Jang A, Peacock J, et al: Mutant p53 increases radioresistance in rat embryo fibroblasts simultaneously transfected with HPV16-E7 and/or H-ras. Oncogene 9:1527-1536, 1994.
88. Bernhard EJ, Kao G, Cox AD, et al: The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res 56:1727-1730, 1996.
89. Packham G, Porter CW, Cleveland JL: c-Myc induces apoptosis and cell cycle progression by separable, yet overlapping, pathways. Oncogene 13:461-469, 1996.
90. Harrington EA, Bennet MR, Fenidi A, et al: c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J 13:3286-3295, 1994.
91. Malyapa RS, Wright WD, Taylor YC, et al: DNA supercoiling changes and nuclear matrix-associated proteins: possible role in oncogene-mediated radioresistance. Int J Radiat Oncol Biol Phys 35:963-973, 1996.
92. Chiarugi V, Magnelli L, Cinelli M, et al: Dominant oncogenes, tumor suppressors, and radiosensitivity. Cell Mol Biol Res 41: 161-166, 1995.
93. Resnicoff M, Abraham D, Yutanawiboonchai W, et al: The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 55:2463-2469, 1995.
94. Singleton JR, Dixit VM, Feldman EL: Type I insulin-like growth factor receptor activation regulates apoptotic proteins. J Biol Chem 271:31791-31794, 1996.
95. Connor R, Kauffmann ZA, Liu Y, et al: Identification of domains of insulin-like growth factor receptor that are required for protection against apoptosis. Mol Cell Biol 17:427-435, 1997.
96. Kolik G, Klippel A, Weber JJ: Anti-apoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3 kinase and Akt. Mol Cell Biol 17:1595-1606, 1997.
97. Dinarello CA: Biologic basis of interleukin-1 in disease. Blood 87:2095-2147, 1996.
98. Friedlander RM, Gagliardini V, Rotello RJ, et al: Functional role of interleukin 1 beta(IL-1 beta) in IL-1 beta-converting enzyme-mediated apoptosis. J Exp Med 184:717-724, 1996.
99. Rodriguez C, Lacasse, Hoang T: Interleukin-1 beta suppresses apoptosis in CD34 positive bone marrow cells through activation of the type I IL-1 receptor. J Cell Physiol 166:387-396, 1996.
100. Braunschweiger PG, Basrur V, Santos O, et al: Radioresistance in murine solid tumors induced by interleukin-1. Radiat Res 145: 150-156, 1996.
101. Neta R, Oppenheim JJ, Wang JM, et al: Synergy of IL-1 and stem cell factor in radioprotection of mice is associated with IL-1 up-regulation of mRNA and protein expression for c-kit or bone marrow cells. J Immunol 153:1536-1543, 1994.
102. Neta R, Perlstein R, Vogel SN, et al: Role of interleukin-6 (IL-6) in protection from lethal irradiation and in endocrine responses to IL-1 and tumor necrosis factor. J Exp Med 175:689-694, 1992.
103. Dalmau SR, Freitas CS, Tabak DG: Interleukin-1 and tumor necrosis factor-alpha as radio- and chemoprotectors of bone marrow. Bone Marrow Transplant 12:551-563, 1993.
104. Rosen EM, Nigam SK, Goldberg ID: Mini-review. Scatter factor and the c-met receptor: A paradigm for mesenchymal: epithelial interaction. J Cell Biol 127:1783-1787, 1994.
105. Rosen EM, Goldberg ID: Scatter factor and angiogenesis. Adv Cancer Res 67:257-279, 1995.
106. Bottaro DP, Rubin JS, Faletto DL, et al: Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251:802-804, 1991.
107. Frisch SM, Francis H: Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124:619-626, 1994.
108. Bardelli A, Longatti P, Albero D, et al: HGF receptor associates with the anti-apoptotic protein BAG-1 and prevents cell death. EMBO J 15:6205-6212, 1996.
109. Fan S, Wang J-A, Yuan R-Q, et al: Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents. Oncogene 17:131-141, 1998.
110. Herrmann M, Lorenz H-M, Voll R, et al: A rapid and simple method for the isolation of apoptotic DNA fragments. Nucl Acids Res 22:5506-5507, 1994.
111. Alley MC, Scudieco DA, Monks A, et al: Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48:589-601, 1988.
112. Goff JP, Shields DS, Boggs SS, et al: Effects of recombinant cytokines on colony formation by irradiated human cord blood CD34+ hematopoietic progenitor cells. Radiat Res 147:61-69, 1997.
113. Yamashita J, Ogawa M, Yamashita S, et al: Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 54: 1630-1633, 1994.
114. Yao Y, Jin L, Fuchs A, et al: Scatter factor protein levels in human breast cancers: Clinicopathologic and biologic correlations. Am J Pathol 149:1707-1717, 1996.
115. Jin L, Yuan R-Q, Fuchs A, et al: Expression of IL-1β in human breast cancer. Cancer 80:421-434, 1997.
116. Rosen EM, Joseph A, Jin L, et al: Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder. J Urol 157:72-78, 1997.
117. Lamszus K, Schmidt NO, Jin L, et al: Scatter factor promotes motility of human glioma and neuromicrovascular endothelial cells. Int J Cancer 75:19-28, 1998.
118. Hallahan DE, Spriggs DR, Beckett MA, et al: Increased tumor necrosis factor-alpha mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci USA 86:10104-10107, 1989.
119. Hallahan DE, Beckett MA, Kufe D, et al: Interaction between recombinant human tumor necrosis factor and radiation in 13 human tumor cell lines. Int J Radiat Oncol Biol Phys 19:69-74, 1990.
120. Rothe M, Sarma V, Dixit VM, et al: TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science 269:1424-1427, 1995.
121. Beg AA, Baltimore D: An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 274:782-784, 1996.
122. Hallahan DE, Dunphy E, Virudachalam S, et al: C-jun and Egr-1 participate in DNA synthesis and cell survival in response to ionizing radiation exposure. J Biol Chem 270:30303-30309, 1995.
123. Mauceri HJ, Hanna NN, Wayne JD, et al: Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res 56:4311-4314, 1996.
124. Haimovitz-Friedman A, Balaban N, McLoughlin M: Protein kinase C mediates basic fibroblast growth factor protection of endothelial cells against radiation-induced apoptosis. Cancer Res 54:2591-2597, 1994.
125. Alon T, Memo I, Itin A, et al: Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1:1024-1028, 1995.
126. Liu ZG, Baskaran R, Lea-Chou ET, et al: Three distinct signalling responses by murine fibroblasts to genotoxic stress. Nature 384:273-276, 1996.
127. Sivaraman VS, Wang H, Nuovo GJ, et al: Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99:1478-1483, 1997.
128. Chen YR, Wang X, Templeton D, et al: Role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. J Biol Chem 271:31929-31936, 1996.
129. Fukasawa K, Vande Woude GF: Synergy between Mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability. Mol Cell Biol 17: 506-518, 1997.
130. Chmura SJ, Nodzenski E, Beckett MA, et al: Loss of ceramide production confers resistance to radiation-induced apoptosis. Cancer Res 57:1270-1275, 1997.
131. Aldridge DR, Arends MJ, Radford IR: Increasing the susceptibility of the rat 208F fibroblast cell line to radiation-induced apoptosis does not alter its clonogenic survival response. Br J Cancer 71:571-577, 1995.
132. Akagi Y, Ito K, Sawada S: Radiation-induced apoptosis and necrosis in Molt-4 cells: a study of dose-effect relationships and their modifications. Int J Radiat Biol 64:47-56, 1993.
133. * burst from vanadyl (4). Anat Rec 245:1-8, 1996.
134. Peters LJ: Radiation therapy tolerance limits. For one or for all? Janeway Lecture. Cancer 77:2379-2385, 1996.
135. Ramsay J, Birrell G: Normal tissue radiosensitivity in breast cancer patients. Int J Radiat Oncol Biol Phys 31:339-344, 1995.
136. Brock WA, Tucker SL, Geara FB, et al: Fibroblast radiosensitivity versus acute and late normal skin responses in patients treated for breast cancer. Int J Radiat Oncol Biol Phys 32:1371-1379, 1995.
137. Birrell GW, Ramsay JR: Induction of p53 protein by gamma radiation in lymphocyte lines from breast cancer patients. Br J Cancer 72:1096-1101, 1995.
138. Dunst J, Gebhart E, Neubauer S: Can an extremely elevated radiosensitivity in patients be recognized by the in vitro testing of lymphocytes? Strahlenther Onkol 171:581-586, 1995.